CHARACTERISTICS OF ADULT PATIENTS TREATED WITH CRIZOTINIB FOR ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH ALK GENE REARRANGEMENT OR ROS1 GENE REARRANGEMENT IN GENERAL HOSPITALS.
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 03 Jun 2019
Price : $35 *
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 29 May 2019 Status changed from recruiting to active, no longer recruiting.
- 01 Nov 2018 New trial record